Related Experiment Video
Updated: Jun 2, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Hyperfractionated split-course thoracic radiation-therapy plus chemotherapy in locally advanced nonsmall cell
R Iaffaioli1, A Tortoriello, G Facchini
1UNIV CAGLIARI,IST MED INTERNA,I-09100 CAGLIARI,ITALY. IST TUMORI NAPOLI,I-80131 NAPLES,ITALY. IST MED LEGALE AM,I-20129 MILAN,ITALY. UNIV NAPLES,FAC MED & CHIRURG 2,IST SCI RADIOL,I-80131 NAPLES,ITALY.
Abstract:
Hyperfractionated split course radiotherapy combined with carboplatin, etoposide and mitomycin C was administered to 76 patients with stage III non-small cell lung cancer. Grade 4 leukopenia occurred in 5 patients; 4 toxic deaths were observed. The overall response rate was 45%, including a 9% rate of complete responses, which lasted > 12 months in four cases. The median survival was 13 months, 2-year progression-free survival 17%, actuarial 2-year survival rate 22%. Age > 65, performance status > 1, no response to prior treatment were predictors of poor outcome. Our treatment plan, particularly because of the long lasting complete responses, warrants further investigation.
